Claims for Patent: 6,458,369
✉ Email this page to a colleague
Summary for Patent: 6,458,369
Title: | Composition comprising tumor cells and extracts and method of using thereof |
Abstract: | The present invention is directed to compositions containing hapten-modified tumor cells and extracts and methods of treating cancer by administering a therapeutically effective amount of a composition containing a tumor cell or tumor cell extract to a subject in need of such treatment. The tumor cells and extracts of the invention and compositions thereof are capable of eliciting T lymphocytes that have a property of infiltrating a mammalian tumor, eliciting an inflammatory immune response to a mammalian tumor, eliciting a delayed-type hypersensitivity response to a mammalian tumor and/or stimulating T lymphocytes in vitro. The invention also relates to an effective vaccination schedule useful for inducing an antitumor response in a mammalian patient suffering from cancer by inducing at least one of the following: tumor necrosis, tumor regression, tumor inflammation, tumor infiltration by activated T lymphocytes, delayed-type hypersensitivity response, and prolongation of patient survival. |
Inventor(s): | Berd; David (Wyncote, PA) |
Assignee: | Thomas Jefferson University (Philadelphia, PA) |
Application Number: | 09/304,859 |
Patent Claims: | 1. A method for inducing an anti-tumor response in a mammalian patient suffering from a tumor, which method comprises administering to said patient a composition comprising a
tumor cell or tumor cell extract with an adjuvant, wherein the tumor cell or tumor cell extract is; (i) conjugated to a hapten; (ii) of the same tumor type as the patient's tumor; (iii) not allogeneic to said patient; and (iv) incapable of growing in
the body of the patient after injection; and repeating said administration at weekly intervals, wherein a therapeutically effective amount of cyclophosphamide is administered only prior to the first administration of the composition, wherein the patient
is not sensitized to the hapten prior to administration of the composition, and wherein the composition elicits an anti tumor response.
2. The method of claim 1, wherein said composition is administered for at least three times. 3. The method of claim 1, wherein said composition is administered for at least six times. 4. The method of claim 1 wherein said therapeutically effective amount of cyclophosphamide comprises administering a dose of about 300 mg/M.sup.2 of cyclophosphamide. 5. The method of claim 1 wherein said tumor cell or extract is selected from the group consisting of melanoma, lung, colon, breast, kidney, prostate, ovarian and leukemia tumor cell or extract. 6. The method of claim 5, wherein said tumor cell or extract is a melanoma tumor cell or extract. 7. The method of claim 1 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, trinitrobenzenesulfonic acid, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof. 8. The method of claim 7 wherein said hapten is dinitrophenyl. 9. The method of claim 1 wherein said adjuvant is selected from the group consisting of Bacillus Calmette-Guerin, QS-21, detoxified endotoxin and a cytokine. 10. The method of claim 1 wherein said mammalian patient is a human. 11. The method of claim 1 wherein said composition comprises at least 10.sup.6 tumor cells or cell equivalents extract per dose. 12. The method of claim 1 wherein said anti-tumor response is at least one of the following: tumor necrosis, tumor regression, tumor inflammation, tumor infiltration by activated T lymphocytes, stable disease and prolongation of patient survival. 13. The method of claim 1, wherein the cyclophosphamide is administered 3 days prior to administration of the composition. 14. The method of claim 1, wherein the composition comprises a maximum of 7.5.times.10.sup.6 cells or cell equivalents per dose. |
Details for Patent 6,458,369
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2018-05-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.